AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Harvey Yu-Li Su

Harvey Yu-Li Su

Chang Gung Memorial Hospital - Taoyuan / Taiwan
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4919108
Chang Gung纪念医院
person_outline Harvey Yu-Li Su's MOST POPULAR ARTICLES
1-) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer New England Journal of Medicine 390 (10), 875-888, 2024
2-) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial The Lancet Oncology 22 (7), 931-945, 2021
3-) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … The Lancet Oncology 21 (12), 1574-1588, 2020
4-) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … The Lancet 390 (10109), 2266-2277, 2017
5-) Belzutifan versus everolimus for advanced renal-cell carcinoma New England Journal of Medicine 391 (8), 710-721, 2024